Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized study of NiCord versus unmanipulated cord blood transplantation in hematologic malignancies
MOH_2018-08-27_002477Phase 3Not yet recruiting
- Sponsor
- Gamida Cell
- Start
- May 2018
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of omidubicel in hematopoietic malignancies, acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML) and 4 more (2 arms), sponsored by Gamida Cell. Planned start May 2018; status: not yet recruiting.
02
Drugs
omidubicel
03
Conditions
hematopoietic malignanciesacute lymphoblastic leukemia (ALL)acute myeloid leukemia (AML)chronic myelogenous leukemia (CML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on MOH_2018-08-27_002477.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2018-08-27_002477.